Last updated: March 12, 2026
What is NDC 42291-0454?
NDC 42291-0454 is a specific drug identified by its National Drug Code. It corresponds to Blenrep (belantamab mafodotin-blmf), a monoclonal antibody designed for the treatment of relapsed or refractory multiple myeloma. Approved by the FDA in August 2020, it targets B-cell maturation antigen (BCMA).
Market Size and Competitive Landscape
Key Indications and Patient Population
- Indication: Multiple myeloma, specifically relapsed or refractory cases.
- Population: Estimated 30,000 to 40,000 patients in the U.S. eligible annually, based on disease prevalence and treatment patterns ([1], [2]).
Existing Therapies and Positioning
Sales Trajectory
- Initial year (2020): Approximate sales of $75 million.
- 2022: Sales increased to $150 million.
- Projection for 2025: Expected to reach $300 million, assuming steady uptake and expanded indications ([4]).
Price Structure and Cost Dynamics
Current Pricing
- List price: Approximately $22,000 per infusion.
- Dosing: 2.5 mg/kg every three weeks, up to eight cycles.
- Average treatment cost: Estimated at $150,000 per patient over the treatment course, considering dosing frequency and patient weight averages.
Reimbursement Landscape
- Reimbursement depends on negotiated payor contracts, with Medicaid, Medicare, and commercial insurers typically covering the majority.
- Out-of-pocket costs: Estimated at 10-15% of total billed charges, subject to patient assistance programs.
Cost Considerations
- Manufacturing: Biologics like Blenrep involve complex manufacturing with high R&D and production costs, influencing retail prices.
- Development costs: Estimated at $1.2 billion to bring biologic oncology drugs like Blenrep to market ([5]).
Market Growth and Future Price Trends
Drivers of Market Growth
- Increased awareness among oncologists.
- Expanded indications, potentially including earlier lines of therapy.
- Evolving combination regimens that integrate Blenrep with other agents.
Price Projection Factors
- Regulatory changes: Potential for price regulation or inflation caps.
- Patent lifecycle: Patent expiration expected around 2030, possibly affecting pricing strategies.
- Market competition: Entry of biosimilars or alternative treatments could lower prices.
Forecasted Price Trends
| Year |
Estimated Price per Treatment Course |
Notes |
| 2023 |
$150,000 |
Current average, with slight negotiation discounts. |
| 2025 |
$140,000 - $160,000 |
Slight decrease due to market competition and negotiations. |
| 2030 |
$130,000 - $150,000 |
Possible biosimilar entry and patent expiry effects. |
Summary of Key Factors Impacting Price and Market Dynamics
| Factor |
Impact |
| Patent expiration |
Potential generic or biosimilar manufacturing leading to price reductions around 2030. |
| Competitive landscape |
New drugs may pressure pricing, especially with more effective or cheaper options. |
| Clinical adoption |
Increased use in combination therapies could raise overall treatment costs. |
| Regulatory environment |
Price controls or value-based pricing reforms could limit price increases. |
Conclusion
Blenrep (NDC: 42291-0454) exhibits a growth trajectory consistent with biologic oncology agents, with current prices averaging $150,000 per course, trending downward as competition increases and biosimilars emerge. Sales are projected to reach $300 million by 2025, with sustained but gradually declining prices until patent expiry influences market dynamics.
Key Takeaways
- Blenrep’s current market size is estimated at $150 million in 2023, with growth driven by expanded use and combinations.
- The drug’s price is approximately $150,000 per treatment course, with slight decreases anticipated as biosimilars and competition grow.
- Market entry of biosimilars around 2030 could reduce prices by 20-30%.
- The lack of immediate generic competition affords some pricing power, but upcoming patent expiry presents long-term risks.
- Pricing negotiations with payors, regulatory policies, and clinical positioning will shape future revenue potential.
FAQs
1. What factors influence the current price of Blenrep?
Manufacturing complexity, R&D costs, market demand, and payer negotiations influence pricing.
2. How does Blenrep compare with other multiple myeloma treatments?
It targets a specific patient population refractory to other therapies, often used in later lines. Its price is comparable to similar biologics but can vary based on dosing and insurance negotiations.
3. When are biosimilars likely to enter the market?
Patent expiry is projected around 2030, after which biosimilar development might commence, potentially reducing prices.
4. What regulatory factors could impact future pricing?
Price controls, value-based pricing reforms, and reimbursement policies can cap or influence prices.
5. How will market competition affect revenue?
New therapies, especially those that are more effective or less costly, could take market share and pressure prices downward.
References
[1] American Cancer Society. (2022). Multiple myeloma statistics.
[2] National Cancer Institute. (2021). Multiple myeloma overview.
[3] Evaluate Pharma. (2023). Biologics market trends.
[4] Company financial reports. (2022-2023). Blenrep sales data.
[5] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.
